Download Free Sample Report

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a mans life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
This report contains market size and forecasts of Oral Drugs for Benign Prostatic Hyperplasia in global, including the following market information:

• Global Oral Drugs for Benign Prostatic Hyperplasia Market Revenue, 2018-2023, 2023-2030, ($ millions)
• Global Oral Drugs for Benign Prostatic Hyperplasia Market Sales, 2018-2023, 2023-2030, (K Units)
• Global top five Oral Drugs for Benign Prostatic Hyperplasia companies in 2022 (%)

The global Oral Drugs for Benign Prostatic Hyperplasia market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Alpha Blockers Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Oral Drugs for Benign Prostatic Hyperplasia include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Viatris, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Oral Drugs for Benign Prostatic Hyperplasia manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Oral Drugs for Benign Prostatic Hyperplasia Market, by Type, 2018-2023, 2023-2030 ($ Millions) & (K Units)

Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, by Type, 2022 (%)

• Alpha Blockers
• 5-alpha Reductase Inhibitors
• Others

Global Oral Drugs for Benign Prostatic Hyperplasia Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (K Units)

Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, by Application, 2022 (%)

• Hospitals
• Drugstores
• Others

Global Oral Drugs for Benign Prostatic Hyperplasia Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (K Units)

Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, By Region and Country, 2022 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Oral Drugs for Benign Prostatic Hyperplasia revenues in global market, 2018-2023 (Estimated), ($ millions)
• Key companies Oral Drugs for Benign Prostatic Hyperplasia revenues share in global market, 2022 (%)
• Key companies Oral Drugs for Benign Prostatic Hyperplasia sales in global market, 2018-2023 (Estimated), (K Units)
• Key companies Oral Drugs for Benign Prostatic Hyperplasia sales share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Eli Lilly
• GlaxoSmithKline
• Astellas Pharma
• Sanofi
• Pfizer
• Abbott
• Allergan
• TEVA
• Viatris
• Novartis
• Merck